Floatz logo

Lamivudine

Relapsed/Refractory Solid Tumors

Thomas MarronSmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

180 Active assets in the Relapsed/Refractory Solid Tumors cohort.

Asset / SponsorPhaseRating
Catequentinib
Nanfang Hospital, Southern Medical University
Phase 3BB
Irinotecan
M.D. Anderson Cancer Center
Phase 2BB
Durvalumab
OHSU Knight Cancer Institute
Phase 2BB
Cediranib
National Cancer Institute (NCI)
Phase 2BB
Sugemalimab
Second Affiliated Hospital of Soochow University
Phase 2BB

View all 50 →

Same molecule, other indications

Lamivudine is also rated in:

lipodystrophyDormant
BBB
Indicative ·
78 / 100
View asset →
HIV infectious diseaseDormant
BBB
Indicative ·
74 / 100
View asset →
chronic hepatitis B virus infectionDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →